This page contains press release content distributed by XPR Media. Members of the editorial and news staff of the USA TODAY Network were not involved in the creation of this content.

Protagonist Announces Submission of NDA for First Icotrokinra U.S. FDA Approval Aiming to Revolutionize Treatment Paradigm for Adults and Adolescents with Plaque Psoriasis

Icotrokinra is a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor

Filing based on unprecedented data package that met all primary endpoints across four Phase 3 studies, including head-to-head superiority comparisons versus deucravacitinib and evaluation of difficult to treat skin sites

Submission underscores potential to offer moderate-to-severe plaque psoriasis patients the standout combination of complete skin clearance, favorable safety profile, and simplicity of a once-daily pill

NEWARK, CALIFORNIA / ACCESS Newswire / July 21, 2025 / Protagonist Therapeutics, Inc. (“Protagonist” or the “Company”) announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) by Johnson & Johnson seeking the first approval of icotrokinra, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and older with moderate to severe plaque psoriasis (PsO). Icotrokinra is uniquely designed to block the IL-23 receptor,which underpins the inflammatory response in plaque PsO and offers potential in other IL-23-mediated diseases.[1], [2], [3] Icotrokinra was jointly discovered and is being developed pursuant to the license and collaboration agreement between Protagonist and Johnson & Johnson.

The NDA includes data from four pivotal Phase 3 studies conducted as part of the ICONIC clinical development program, including ICONIC-LEAD, a ICONIC-TOTAL,b ICONIC-ADVANCE 1 and ICONIC-ADVANCE 2.c Treatment with icotrokinra met all primary and co-primary endpoints across the development program among adults and pediatric patients 12 years of age and older with moderate-to-severe plaque PsO, demonstrating significant skin clearance and a favorable safety profile in a once-daily pill. Results from the ICONIC-ADVANCE 1 & 2 studies show icotrokinra achieved co-primary endpoints and showed superiority to deucravacitinib in moderate-to-severe plaque PsO. Across all studies, pooled safety data showed a similar proportion of patients experienced adverse events between icotrokinra (49.1%) and placebo (51.9%) groups, with no new safety signals identified to date.[4], [5], [6], [7], [8]

“The very comprehensive clinical data package included in the NDA filing demonstrate that icotrokinra has the potential to disrupt the current treatment paradigm and transform how physicians and patients approach plaque psoriasis care,” said Dinesh V. Patel, Ph.D., President and Chief Executive Officer at Protagonist. “All four pivotal Phase 3 trials achieved impressive efficacy results and favorable safety profile with a convenient, targeted once-a-day oral peptide therapy. We look forward to additional data in the ongoing studies that may expand the future application of icotrokinra in indications such as psoriatic arthritis, ulcerative colitis, and Crohn’s disease.”

“This NDA marks a first for an asset discovered at Protagonist and further validates the potential of our peptide discovery and development platform. It’s a testament to great innovation and perseverance, and an outstanding long-term collaboration with Johnson & Johnson,” said Dr. Patel. “Protagonist is at the forefront of discovery and development of novel peptide therapeutics that offer the efficacy and specificity of injectable biologics with the convenience of oral delivery in various disease areas including inflammation, immunomodulatory and metabolic diseases.”

Data submitted to the FDA as part of the NDA include:

  • Results from the Phase 3 ICONIC-LEAD study, presented as a late-breaking abstract at the 2025 American Academy of Dermatology (AAD) Annual Meeting, showed icotrokinra successfully met the co-primary endpoints of Investigator’s Global Assessment (IGA)d score of 0/1 (clear or almost clear skin) and Psoriasis Area and Severity Index (PASI) e 90 compared to placebo at Week 16.4

  • A subgroup analysis of ICONIC-LEAD, presented at the 2025 World Congress of Pediatric Dermatology (WCPD), which demonstrated that pediatric patients treated with once daily icotrokinra achieved higher rates of clear or almost clear skin at Week 16 compared to patients receiving placebo, with no new safety signals identified.5

  • Data from the Phase 3 ICONIC-TOTAL study, presented at the 2025 Society for Investigative Dermatology (SID) Annual Meeting, highlighted the potential of icotrokinra in patients with difficult-to-treat scalp and genital psoriasis.6

  • Results from the Phase 3 ICONIC-ADVANCE 1 & ICONIC-ADVANCE 2 studies, that further reinforced the overall efficacy profile met co-primary endpoints of IGA 0/1 and PASI 90 versus placebo at Week 16. Icotrokinra also met all key secondary endpoints at Weeks 16 and 24 that measured superiority to deucravacitinib in patients with moderate-to-severe plaque PsO.7,8 Comprehensive results are being prepared for presentation at a future medical meeting.

  • Long-term data from the ICONIC development program, including at least 52-weeks of treatment for ICONIC-LEAD and ICONIC-TOTAL, and results from a randomized withdrawal analysis evaluating the durability of response, are being prepared for presentation at a future medical meeting.

Johnson & Johnson has also initiated the Phase 3 ICONIC-ASCENDf study, the first-ever head-to-head study seeking to demonstrate the superiority of an oral pill, icotrokinra, compared to an injectable biologic, ustekinumab, representing an important step forward in psoriasis research.

Editor’s notes:

  1. ICONIC-LEAD is a Phase 3 randomized controlled trial (RCT) evaluating the efficacy and safety of icotrokinra compared with placebo in 684 participants (icotrokinra=456; placebo=228) 12 years of age or older with moderate-to-severe plaque PsO, with the higher efficacy bar of PASI 90 and IGA score of 0/1 with at least a 2-grade improvement as co-primary endpoints. ICONIC-LEAD enrolled 66 pediatric patients.

  2. ICONIC-TOTAL is a Phase 3 RCT evaluating the efficacy and safety of icotrokinra compared with placebo for the treatment of plaque PsO in 311 participants (icotrokinra=208; placebo=103) with at least moderate severity affecting special areas (e.g., scalp, genital and/or hands and feet) with overall IGA score of 0 or 1 with at least a 2-grade improvement as the primary endpoint.

  3. ICONIC- ADVANCE 1 & 2 are Phase 3 RCTs evaluating the efficacy and safety of icotrokinra compared with placebo and deucravacitinib in participants with moderate-to-severe plaque PsO with PASI 90 and IGA score of 0/1 with at least a 2-grade improvement as co-primary endpoints.

  4. The IGA is a five-point scale with a severity score ranging from 0 to 4, where 0 indicates clear, 1 is minimal, 2 is mild, 3 is moderate and 4 indicates severe disease.[9]

  5. The PASI score grades the amount of surface area on each body region that is covered by psoriasis plaques and the severity of plaques for their redness, thickness and scaliness.[10] PASI 90 corresponds to an improvement of >=90% in PASI score from baseline.10

  6. ICONIC-ASCEND is a Phase 3 RCT and the first-ever head-to-head study seeking to demonstrate the superiority of an oral pill, icotrokinra, compared to an injectable biologic, ustekinumab in moderate-to-severe plaque PsO.

About the ICONIC Clinical Development Program
The pivotal Phase 3 ICONIC clinical development program of icotrokinra (in adult and pediatric individuals with moderate-to-severe plaque PsO) was initiated with two studies in Q4 2023 – ICONIC-LEAD and ICONIC-TOTAL – pursuant to the license and collaboration agreement between Protagonist Therapeutics, Inc. and Janssen Biotech, Inc., a Johnson & Johnson company. The ICONIC program is being conducted by Johnson & Johnson.[11]

ICONIC-LEAD (NCT06095115) is a randomized controlled trial (RCT) to evaluate the efficacy and safety of icotrokinra compared with placebo in participants with moderate-to-severe plaque PsO, with PASI 90 and IGA score of 0 or 1 with at least a 2-grade improvement as co-primary endpoints. [12]

ICONIC-TOTAL (NCT06095102) is an RCT to evaluate the efficacy and safety of icotrokinra compared with placebo for the treatment of PsO in participants with at least moderate severity affecting special areas (e.g., scalp, genital, and/or hands and feet) with overall IGA score of 0 or 1 with at least a 2-grade improvement as the primary endpoint.[13]

Other Phase 3 studies in the development program include ICONIC-ADVANCE 1 (NCT06143878) and ICONIC-ADVANCE 2 (NCT06220604), which evaluate the efficacy and safety of icotrokinra compared with both placebo and deucravacitinib in adults with moderate-to-severe plaque PsO. [14], [15] ICONIC-ASCEND will evaluate the efficacy and safety of icotrokinra compared with placebo and ustekinumab in participants with moderate-to-severe plaque psoriasis. ICONIC-PsA 1 (NCT06878404) and ICONIC-PsA 2 (NCT06807424) will evaluate the efficacy and safety of icotrokinra compared to placebo in participants with active psoriatic arthritis.[16], [17]

About Plaque Psoriasis
Plaque psoriasis (PsO) is a chronic immune-mediated disease resulting in overproduction of skin cells, which causes inflamed, scaly plaques that may be itchy or painful.[18] It is estimated that 8 million Americans and more than 125 million people worldwide live with the disease.[19] Nearly one-quarter of all people with plaque PsO have cases that are considered moderate to severe. On Caucasian skin, plaques typically appear as raised, red patches covered with a silvery white buildup of dead skin cells or scale.19 On skin of color, the plaques may appear darker, thicker and more of a purple, gray, or dark brown color. Plaques can appear anywhere on the body, although they most often appear on the scalp, knees, elbows, and torso.[20] Living with plaque PsO can be a challenge and impact life beyond a person’s physical health, including emotional health, relationships, and handling the stressors of life.[21] Psoriasis on highly visible areas of the body or sensitive skin, such as the scalp, hands, feet, and genitals, can have an increased negative impact on quality of life.18, [22]

About Icotrokinra (JNJ-77242113, JNJ-2113)
Investigational icotrokinra is the first targeted oral peptide designed to selectively block the IL-23 receptor,1 which underpins the inflammatory response in moderate-to-severe plaque PsO, ulcerative colitis, and offers potential in other IL-23-mediated diseases.2,3 Icotrokinra binds to the IL-23 receptor with single-digit picomolar affinity and demonstrates potent, selective inhibition of IL-23 signaling in human T cells.[23] The license and collaboration agreement established between Protagonist Therapeutics, Inc. and Janssen Biotech, Inc., a Johnson & Johnson company, in 2017 enabled the companies to work together to discover and develop oral peptide IL-23 receptor antagonists that ultimately led to icotrokinra.[24]

Icotrokinra was jointly discovered and is being developed pursuant to the license and collaboration agreement between Protagonist and Johnson & Johnson. Johnson & Johnson retains exclusive worldwide rights to develop icotrokinra in Phase 2 clinical trials and beyond, and to commercialize compounds derived from the research conducted pursuant to the agreement against a broad range of indications.[25], [26], [27]

Icotrokinra is being studied in the pivotal Phase 3 ICONIC clinical development program in moderate-to-severe plaque psoriasis and active psoriatic arthritis and the Phase 2b ANTHEM-UC study in moderately to severely active ulcerative colitis.

About Protagonist

Protagonist Therapeutics is a discovery through late-stage development biopharmaceutical company. Two novel peptides derived from Protagonist’s proprietary discovery platform have completed Phase 3 clinical development, with one New Drug Application submitted to the FDA in 2025 and a second NDA submission expected in the fourth quarter of 2025. An NDA for the treatment of psoriasis has been submitted for icotrokinra (formerly, JNJ-2113). Icotrokinra is a first-in-class investigational targeted oral peptide that selectively blocks the Interleukin-23 receptor (“IL-23R”), which is licensed to Janssen Biotech, Inc., a Johnson & Johnson company. Protagonist and Johnson & Johnson scientists jointly discovered icotrokinra under the companies’ IL-23R research collaboration. Protagonist was primarily responsible for the development of icotrokinra through Phase 1, with Johnson & Johnson assuming responsibility for development in Phase 2 and beyond. Rusfertide, a mimetic of the natural hormone hepcidin, recently completed Phase 3 development for the rare blood disorder polycythemia vera (PV). An NDA is expected to be submitted in the fourth quarter of 2025. Rusfertide is being co-developed and will be co-commercialized with Takeda Pharmaceuticals pursuant to a worldwide collaboration and license agreement entered into in 2024 under which the Company remains primarily responsible for development through NDA filing. The Company also has a number of pre-clinical stage drug discovery programs addressing clinically and commercially validated targets, including IL-17 oral peptide antagonist PN-881, obesity triple agonist peptide PN-477, and oral hepcidin.

More information on Protagonist, its pipeline drug candidates, and clinical studies can be found on the Company’s website at https://www.protagonist-inc.com/.

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding the potential benefits of icotrokinra in psoriasis and other potential indications and our expectations regarding icotrokinra clinical development. In some cases, you can identify these statements by forward-looking words such as “anticipate,” “believe,” “may,” “will,” “expect,” or the negative or plural of these words or similar expressions. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, our ability to develop and commercialize our product candidates, our ability to earn milestone payments under our collaboration agreements with Janssen and Takeda, our ability to use and expand our programs to build a pipeline of product candidates, our ability to obtain and maintain regulatory approval of our product candidates, our ability to operate in a competitive industry and compete successfully against competitors that have greater resources than we do, and our ability to obtain and adequately protect intellectual property rights for our product candidates. Additional information concerning these and other risk factors affecting our business can be found in our periodic filings with the Securities and Exchange Commission, including under the heading “Risk Factors” contained in our most recently filed periodic reports on Form 10-K and Form 10-Q filed with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release.

Investor Relations Contact

Corey Davis, Ph.D.
LifeSci Advisors
cdavis@lifesciadvisors.com
+1 212 915 2577

Media Relations Contact

Virginia Amann
ENTENTE Network of Companies
virginiaamann@ententeinc.com
+1 833 500 0061 ext. 1

[1] Bissonnette R, et al. Data presentation. A phase 2, randomized, placebo-controlled, dose-ranging study of oral JNJ-77242113 for the treatment of moderate-to-severe plaque psoriasis: FRONTIER 1. Presented at WCD 2023, July 3-8.

[2] Razawy W, et al. The role of IL‐23 receptor signaling in inflammation‐mediated erosive autoimmune arthritis and bone remodeling. Eur J Immunol . 2018 Feb; 48(2): 220-229.

[3] Tang C, et al. Interleukin-23: as a drug target for autoimmune inflammatory diseases. Immunology . 2012 Feb; 135(2): 112-124.

[4] Bissonnette, R et al. Icotrokinra, a Targeted Oral Peptide That Selectively Blocks the Interleukin-23-Receptor, for the Treatment of Moderate-to-Severe Plaque Psoriasis: Results Through Week 24 of the Phase 3, Randomized, Double-blind, Placebo-Controlled ICONIC-LEAD Trial. Late-breaking research presentation (Abstract #66708) at the American Academy of Dermatology (AAD) 2024 Annual Meeting. March 2025.

[5] Eichenfield, L et al. Efficacy and Safety of Icotrokinra, a Novel Targeted Oral Peptide (IL-23R-inhibitor), in Adolescents With Moderate-to- Severe Plaque Psoriasis: Subgroup Analyses From a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study (ICONIC-LEAD). Presented at the World Congress of Pediatric Dermatology (Abstract #0054). April 2025.

[6] Gooderham, M.J. et al. Phase 3 results from an innovative trial design of treating plaque psoriasis involving difficult-to-treat, high-impact sites with icotrokinra, a targeted oral peptide that selectively inhibits the IL-23-receptor. Presented at the 2025 Society for Investigative Dermatology (Abstract #LB1142). May 2025.

[7] Data on file.

[8] Data on file.

[9] Simpson E, Bissonnette R, Eichenfield LF, et al. The validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD™): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis [published online April 25, 2020]. J Am Acad Dermatol. https://www.jaad.org/article/S0190-9622(20)30720-9/abstract. Accessed July 2025.

[10] Thompson Jr, D. How the Psoriasis Area and Severity Index works. Everyday Health. Available at: https://prpsurvivalguide.org/psoriasis-area-and-severity-index-pasi/. Accessed July 2025.

[11] Protagonist Therapeutics. Press release. Protagonist announces advancement of JNJ-2113 across multiple indications. Available at: https://www.accesswire.com/791174/protagonist-announces-advancement-of-jnj-2113-across-multiple-indications. Accessed July 2025.

[12] Clinicaltrials.gov. A study of JNJ-2113 in adolescent and adult participants with moderate-to-severe plaque psoriasis (ICONIC-LEAD). Identifier NCT06095115. https://classic.clinicaltrials.gov/ct2/show/NCT06095115. Accessed July 2025.

[13] Clinicaltrials.gov. A study of JNJ-2113 for the treatment of participants with plaque psoriasis involving special areas (scalp, genital, and/or palms of the hands and the soles of the feet) (ICONIC-TOTAL). Identifier NCT06095102. https://classic.clinicaltrials.gov/ct2/show/NCT06095102. Accessed July 2025.

[14] Clinicaltrials.gov. A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis. Identifier NCT06143878. https://clinicaltrials.gov/study/NCT06143878?term=jnj-77242113&rank=10. Accessed July 2025.

[15] Clinicaltrials.gov. A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2). Identifier NCT06220604. https://clinicaltrials.gov/study/NCT06220604. Accessed July 2025.

[16] Clinicaltrials.gov. A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic Arthritis (ICONIC-PsA 1). Identifier NCT06878404. https://clinicaltrials.gov/study/NCT06878404

[17] A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced Participants With Active Psoriatic Arthritis (ICONIC-PsA 2). Identifier NCT06807424. https://clinicaltrials.gov/study/NCT06807424

[18] National Psoriasis Foundation. About Psoriasis. Available at: https://www.psoriasis.org/about-psoriasis. Accessed July 2025.

[19] National Psoriasis Foundation. Psoriasis Statistics. Available at: https://www.psoriasis.org/content/statistics. Accessed July 2025.

[20] National Psoriasis Foundation. Plaque Psoriasis. Available at: https://www.psoriasis.org/plaque/. Accessed July 2025.

[21] National Psoriasis Foundation. Life with Psoriasis. Available at: https://www.psoriasis.org/life-with-psoriasis/. Accessed July 2025.

[22] National Psoriasis Foundation. High Impact Sites. Available at: https://www.psoriasis.org/high-impact-sites/. Accessed July 2025.

[23] Pinter A, et al. Data Presentation. JNJ-77242113 Treatment Induces a Strong Systemic Pharmacodynamic Response Versus Placebo in Serum Samples of Patients with Plaque Psoriasis: Results from the Phase 2, FRONTIER 1 Study. Presented at EADV 2023, October 11-14.

[24] Johnson & Johnson. Press release. Janssen enters into worldwide exclusive license and collaboration agreement with Protagonist Therapeutics, Inc. for the oral Interlukin-23 receptor antagonist drug candidate for the treatment of Inflammatory Bowel Disease. Available at: https://www.jnj.com/media-center/press-releases/janssen-enters-into-worldwide-exclusive-license-and-collaboration-agreement-with-protagonist-therapeutics-inc-for-the-oral-interlukin-23-receptor-antagonist-drug-candidate-for-the-treatment-of-inflammatory-bowel-disease. Accessed July 2025.

[25] Protagonist Therapeutics. Press release. Protagonist Therapeutics announces amendment of agreement with Janssen Biotech for the continued development and commercialization of IL-23 antagonists. Available at: https://feeds.issuerdirect.com/news-release.html?newsid=8739644264127846&symbol=PTGX. Accessed July 2025.

[26] Protagonist Therapeutics. Press release. Protagonist Reports positive results from Phase 1 and pre-clinical studies of oral Interleukin-23 receptor antagonist JNJ-2113. Available at: https://feeds.issuerdirect.com/news-release.html?newsid=8812150281946506&symbol=PTGX. Accessed July 2025.

[27] Protagonist Therapeutics. Press release. Protagonist Therapeutics announces positive topline results for Phase 2b FRONTIER 1 clinical trial of oral IL-23 receptor antagonist JNJ-2113 (PN-235) in psoriasis. Available at: https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/protagonist-reports-positive-top-line-results-from-phase-2b-study-of-i-997892. Accessed July 2025.

SOURCE: Protagonist Therapeutics

View the original press release on ACCESS Newswire

Information contained on this page is provided by an independent third-party content provider. XPRMedia and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact pressreleases@xpr.media

Primus Sounds Alarm on Chronic Venous Insufficiency as President Trump’s Diagnosis Sparks National Focus

Primus Sounds Alarm on Chronic Venous Insufficiency as President Trump’s Diagnosis Sparks National Focus

SCOTTSDALE, ARIZONA / ACCESS Newswire / July 24, 2025 / Following reports of President Donald J. Trump’s diagnosis with Chronic Venous Insufficiency (CVI), Primus Pharmaceuticals,…

July 24, 2025

Wudinna Gold Project Rights Acquisition Completed

Wudinna Gold Project Rights Acquisition Completed

HIGHLIGHTS Acquisition of 279koz Au Wudinna Gold Project approved by vendor shareholders1 Barton now has binding rights to project ownership pending tenement grant or transfer…

July 24, 2025

Does LASIK Affect Depth Perception: Tersigni Vision Explores the Facts

Does LASIK Affect Depth Perception: Tersigni Vision Explores the Facts

Depth perception is a fundamental aspect of vision, affecting everything from driving and playing sports to simple daily tasks. As LASIK surgery continues to be…

July 24, 2025

A New Era of Fashion Collaboration Begins: Introducing the Global Fashion Membership Platform

A New Era of Fashion Collaboration Begins: Introducing the Global Fashion Membership Platform

Connect with designers, factories, and fashion professionals worldwide. Grow your network, find partners, and unlock new business opportunities across the global fashion supply chain. Jul….

July 24, 2025

Unveiling the Mind Machine That Makes Meditation Easy: MindMachines.com’s ROSHIwave IN-SIGHT

Unveiling the Mind Machine That Makes Meditation Easy: MindMachines.com’s ROSHIwave IN-SIGHT

MindMachines.com has introduced a new advancement in brainwave technology with its ROSHIwave IN-SIGHT Mind Machine. This device is a major step forward in personal wellness…

July 24, 2025

Foundational Builders Corporation Announces Florida Expansion, Prioritizing Structural Resilience and Regulatory Compliance

Foundational Builders Corporation Announces Florida Expansion, Prioritizing Structural Resilience and Regulatory Compliance

TAMPA, FL / ACCESS Newswire / July 24, 2025 / Foundational Builders Corporation (FB Corp), a national construction and structural retrofit company, has officially expanded…

July 24, 2025

Encore Data Products Unveils Iris Pen Scanners at ISTE After Show Launch

Encore Data Products Unveils Iris Pen Scanners at ISTE After Show Launch

Encore Data Products has introduced a new offering in its suite of technology solutions after a show at the ISTELive25 Conference in San Antonio, Texas…

July 24, 2025

Christian Fischbacher Elevates High-End Home Textiles with Luxurious and Sustainable Designs

Christian Fischbacher Elevates High-End Home Textiles with Luxurious and Sustainable Designs

Christian Fischbacher Bed & Bath AG is announcing a renewed commitment to creating luxury home textiles. They’re building on their long-standing expertise in premium bedding,…

July 24, 2025

All Pro Overhead: Leading Garage Door Opener Repair Services in East Sacramento

All Pro Overhead: Leading Garage Door Opener Repair Services in East Sacramento

All Pro Overhead Garage Doors, a trusted name with over two decades in the business, is making headway in garage door services, with a special…

July 24, 2025

Apex Money Lending Group Launches Swift Commercial Loan Solutions for Colorado’s Real Estate Innovators

Apex Money Lending Group Launches Swift Commercial Loan Solutions for Colorado’s Real Estate Innovators

Apex Money Lending Group LLC is rolling out a wide array of commercial real estate loans tailored for businesses and real estate investors in Colorado….

July 24, 2025

UptimeAI Wins Frost & Sullivan’s 2025 North American New Product Innovation Award

UptimeAI Wins Frost & Sullivan’s 2025 North American New Product Innovation Award

Recognized for AI-Driven Operational Excellence [ OEx ] in the Heavy Asset Industry SAN FRANCISCO, CA / ACCESS Newswire / July 24, 2025 / UptimeAI,…

July 24, 2025

Ray Van Tent & Equipment Expands Services with New Partnerships and Rental Options for Event Success

Ray Van Tent & Equipment Expands Services with New Partnerships and Rental Options for Event Success

Ray Van Tent & Equipment is excited to announce the expansion of its event services, now offering a wider selection of rental equipment and new…

July 24, 2025

LASIK in Northern Colorado: Personalized Vision Correction from a National Leader in Refractive Surgery

LASIK in Northern Colorado: Personalized Vision Correction from a National Leader in Refractive Surgery

For those considering LASIK in Northern Colorado, Vance Thompson Vision offers nationally recognized care delivered by an experienced surgical team using the most advanced laser…

July 24, 2025

Discover Vegetable Chow Mein in Las Vegas at Kung Fu Thai & Chinese Restaurant

Discover Vegetable Chow Mein in Las Vegas at Kung Fu Thai & Chinese Restaurant

Kung Fu Thai & Chinese Restaurant recently announced an exciting addition to its popular noodle lineup, bringing diners the Best Chow Mein Combination in Las…

July 24, 2025

Discover the Best Vegetable Chow Mein in Las Vegas at Kung Fu Thai & Chinese Restaurant

Discover the Best Vegetable Chow Mein in Las Vegas at Kung Fu Thai & Chinese Restaurant

Kung Fu Thai & Chinese Restaurant recently announced an exciting addition to its popular noodle lineup, bringing diners the Best Chow Mein Combination in Las…

July 24, 2025

Manufacturers Floor Covering Outlet Launches Residential Flooring Installers in Tempe

Manufacturers Floor Covering Outlet Launches Residential Flooring Installers in Tempe

Manufacturers Floor Covering Outlet has announced a big step forward in expanding their services, showing their dedication to offering top-notch floor solutions to more people….

July 24, 2025

Go Industries Inc. Unveils Chevy Grille Guard with Winch for Enhanced Protection and Utility

Go Industries Inc. Unveils Chevy Grille Guard with Winch for Enhanced Protection and Utility

Go Industries Inc. has announced a new product that aims to provide better protection for vehicles. This Chevy grille guard with winch is designed to…

July 24, 2025

International House UC Berkeley Announces New Board Leadership and Directors

International House UC Berkeley Announces New Board Leadership and Directors

Newly-added directors will serve for the 2025-2026 term BERKELEY, CA / ACCESS Newswire / July 24, 2025 / International House Berkeley (I-House Berkeley), the multicultural…

July 24, 2025

As U.S. Workers Seek Upskilling and New Jobs, ACE Offers Affordable Courses and Programs in Alignment with In-Demand Skills

As U.S. Workers Seek Upskilling and New Jobs, ACE Offers Affordable Courses and Programs in Alignment with In-Demand Skills

A leading provider of quality, affordable online degrees leverages insight from data, employers and workers to ensure its programs teach skills that industry needs today…

July 24, 2025

FuzeHub Brings New York State Innovation Summit to Rochester October 29 – 30

FuzeHub Brings New York State Innovation Summit to Rochester October 29 – 30

Registration now open for the multi-day event that showcases the Empire State’s latest disruptive technologies ROCHESTER, NY / ACCESS Newswire / July 24, 2025 /…

July 24, 2025

Applied DNA Announces New Follow-On LineaDNA Order from Global IVD Manufacturer for Use in Cancer Diagnostic Application

Applied DNA Announces New Follow-On LineaDNA Order from Global IVD Manufacturer for Use in Cancer Diagnostic Application

STONY BROOK, NY / ACCESS Newswire / July 24, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (“Applied DNA” or the “Company”), a leader in synthetic…

July 24, 2025

Trump Lit the Match, SMX Is the Accelerant In The Newly Legitimized Digital Market

Trump Lit the Match, SMX Is the Accelerant In The Newly Legitimized Digital Market

NEW YORK CITY, NEW YORK / ACCESS Newswire / July 24, 2025 / With a single stroke of his pen, President Donald Trump changed the…

July 24, 2025

EdgeCore Digital Infrastructure Completes $235 Million ABS Financing

EdgeCore Digital Infrastructure Completes $235 Million ABS Financing

Securitization comprised of green bonds reflects EdgeCore’s commitment to sustainable development and operations practices DENVER, CO / ACCESS Newswire / July 24, 2025 / EdgeCore…

July 24, 2025

Telomir Pharmaceuticals Reports Telomir-1’s Unique Profile Restores Mitochondrial Health While Improving Oxidative Stress Without Promoting Cell Proliferation in Diseased Human Cell Lines Highlighting Potential Relevance to Neurodegenerative Pathways in Alzheimer’s and Parkinson’s

Telomir Pharmaceuticals Reports Telomir-1’s Unique Profile Restores Mitochondrial Health While Improving Oxidative Stress Without Promoting Cell Proliferation in Diseased Human Cell Lines Highlighting Potential Relevance to Neurodegenerative Pathways in Alzheimer’s and Parkinson’s

This unique cellular activity may help restore energy balance and improve essential cell functions such as protein synthesis and membrane stability in diseases like Parkinson’s…

July 24, 2025

EON Resources Inc. Provides Insight into Preliminary Second Quarter 2025 Results

EON Resources Inc. Provides Insight into Preliminary Second Quarter 2025 Results

HOUSTON, TEXAS / ACCESS Newswire / July 24, 2025 / EON Resources Inc. (NYSE American:EONR) (“EON” or the “Company”) is an independent upstream energy company…

July 24, 2025

Eskay Expands its High-Grade Gold Vein System at its 100% Controlled and Consolidated Eskay Project in the Golden Triangle

Eskay Expands its High-Grade Gold Vein System at its 100% Controlled and Consolidated Eskay Project in the Golden Triangle

TORONTO, ON / ACCESS Newswire / July 24, 2025 / Eskay Mining Corp. (“Eskay” or the “Company”) (TSXV:ESK)(OTC PINK:ESKYF)(Frankfurt:KN7)(WKN:A0YDPM) is pleased to provide an update…

July 24, 2025

HyProMag USA Enters Into Agreement with Global Electronics Recycler, Intelligent Lifecycle Solutions, for Feedstock Supply and Pre-Processing Site Share in South Carolina and Nevada

HyProMag USA Enters Into Agreement with Global Electronics Recycler, Intelligent Lifecycle Solutions, for Feedstock Supply and Pre-Processing Site Share in South Carolina and Nevada

LONDON, UK AND VANCOUVER, BC / ACCESS Newswire / July 24, 2025 / CoTec Holdings Corp. (TSXV:CTH)(OTCQB:CTHCF) (“CoTec”) and Mkango Resources Ltd. (AIM:MKA)(TSXV:MKA) (“Mkango”) are…

July 24, 2025

Liberty Personal Loans Support Australians to Unlock Local Travel

Liberty Personal Loans Support Australians to Unlock Local Travel

With domestic travel on the rise and Australians looking to explore their own backyard, Liberty says personal loans could help turn travel dreams into reality….

July 24, 2025

Tharimmune Announces Pricing of $1.74 Million Registered Direct Public Offering of Common Stock and Warrants

Tharimmune Announces Pricing of $1.74 Million Registered Direct Public Offering of Common Stock and Warrants

RED BANK, NJ / ACCESS Newswire / July 23, 2025 / Tharimmune, Inc. (the “Company” and “Tharimmune”) (Nasdaq Capital Market:THAR), a clinical-stage biotechnology company committed…

July 24, 2025

Liberty Business Loans Offer Flexibility This Financial Year

Liberty Business Loans Offer Flexibility This Financial Year

With key changes to business regulations now in effect, Liberty has flexible business loans to support Australian businesses this financial year. MELBOURNE, AU / ACCESS…

July 24, 2025

DivX Unveils Revamped Resource Guide to Help Users Easily Convert MKV to MP4

DivX Unveils Revamped Resource Guide to Help Users Easily Convert MKV to MP4

Updated free guide provides step-by-step instructions for high-quality video conversion, addressing common compatibility issues for tech consumers and video enthusiasts. Jul. 23, 2025 / PRZen…

July 23, 2025

Matthew Wright Elected Chair of AAJ Trucking Litigation Group

Matthew Wright Elected Chair of AAJ Trucking Litigation Group

Nashville attorney to lead national group focused on advancing truck safety and legal advocacy NASHVILLE, TN / ACCESS Newswire / July 23, 2025 / Matthew…

July 23, 2025

Homesafe Wealth Release: Offering Equity With Peace of Mind

Homesafe Wealth Release: Offering Equity With Peace of Mind

SYDNEY, AU / ACCESS Newswire / July 23, 2025 / Accessing equity in your home can be a complex and detailed process that can leave…

July 23, 2025

LASIK in Cedar Rapids, IA: Expert Laser Vision Correction from a National Leader in Refractive Surgery

LASIK in Cedar Rapids, IA: Expert Laser Vision Correction from a National Leader in Refractive Surgery

For individuals considering LASIK in Cedar Rapids, Vance Thompson Vision offers world-class care, cutting-edge technology, and a surgical team known nationally for its experience and…

July 23, 2025

Electrifying Solutions: Dietz Electric and Orange1 Motors Transforming the Industry

Electrifying Solutions: Dietz Electric and Orange1 Motors Transforming the Industry

Dietz Electric, a renowned authority in electric motor services, is elevating industry standards through its exclusive partnership with Orange1 Motors. Known for blending over five…

July 23, 2025

Eco-Friendly Hot Water Solutions: Oekoboiler Swiss AG Revolutionizes with Smart and Sustainable Technology

Eco-Friendly Hot Water Solutions: Oekoboiler Swiss AG Revolutionizes with Smart and Sustainable Technology

Oekoboiler Swiss AG is committed to advancing sustainable and efficient solutions for hot water needs. Based in Switzerland, the company excels in producing heat pump…

July 23, 2025

El Dorado Hills Residents Rely on All Pro Overhead for 24/7 Garage Door Opener Repair

El Dorado Hills Residents Rely on All Pro Overhead for 24/7 Garage Door Opener Repair

All Pro Overhead Garage Doors is stepping up its game by paying special attention to Garage Door Opener Repair in El Dorado Hills. With over…

July 23, 2025

ARC Restoration Unveils Advanced Fire Damage Solutions in Denver

ARC Restoration Unveils Advanced Fire Damage Solutions in Denver

ARC Restoration, a top disaster cleanup and restoration company based in Denver, Colorado, has rolled out new and improved fire damage restoration services. These enhanced…

July 23, 2025

Lone Wolf Exteriors Expands to Cedar Park, TX: Cut Window Replacement Cost with Energy-Efficient Solutions!

Lone Wolf Exteriors Expands to Cedar Park, TX: Cut Window Replacement Cost with Energy-Efficient Solutions!

Lone Wolf Exteriors, a respected company based in Dallas-Fort Worth, Texas, is expanding its operations to include the Austin area. They are known for their…

July 23, 2025

AI Transforming the POD Industry: Innovations and Opportunities

AI Transforming the POD Industry: Innovations and Opportunities

Artificial intelligence is reshaping web-to-print solutions, enhancing design efficiency, quality control, and personalization for businesses and consumers. Jul. 23, 2025 / PRZen / BURBANK, Calif….

July 23, 2025